David L. Douglass
General Partner @ Delphi Ventures
San Francisco, United States
David L. Douglass is a Series C investor at Delphi Ventures in San Francisco focused on Health Care and Biotechnology. David L. Douglass is the General Partner at Delphi Ventures.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries David L. Douglass invests in
Health CareBiotechnologyMedicalTherapeuticsMedical Device
Stages David L. Douglass invests in
Series CSeries DSeries BSeries EFunding Round
Countries David L. Douglass invests in
United States
Investment Focus
Industry
- Health Care 11 (65%)
- Biotechnology 8 (47%)
- Medical 5 (29%)
- Therapeutics 4 (24%)
- Medical Device 4 (24%)
Stage
- Series C 4 (24%)
- Series D 4 (24%)
- Series B 3 (18%)
- Series E 2 (12%)
- Funding Round 2 (12%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AEGEA Medical
|
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-basedprocedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California. | $40M / Series D / Jan 02, 2018 | |
|
AEGEA Medical
|
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-basedprocedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California. | $36M / Series C / May 04, 2015 | |
Revance Therapeutics
|
Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as EssentiaBiosystems. | $33M / Series E / Apr 02, 2013 | |
Astute Medical
|
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment.The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development. | $40.4M / Series C / Jun 07, 2012 | |
|
AEGEA Medical
|
AEGEA Medical is pioneering the application of its Adaptive Vapor Ablation technology to deliver therapies that provide high quality patient outcomes to a wider range of patients. AEGEA’s FDA approved water vapor technology enables the delivery of a safe and effective endometrial ablation for the treatment of menorrhagia in a simple, office-basedprocedure that takes only minutes. With a vision to expand safe and effective treatment options to more patients, and provide physicians with the confidence and convenience necessary to perform office-based procedures, AEGEA is inspiring new approaches to women’s healthcare. Founded in 2008, AEGEA Medical is located in in Menlo Park, California. | $13.4M / Series B / May 25, 2011 | |
Cameron Health
|
Cameron Health, Inc., a development stage medical device company, is creating the next generation of implantable electronic device utilizing state-of-the-art technologies. They are a team of specialized, high technology, creative individuals with decades of experience in solving difficult medical problems. Their current target is the development ofa family of devices that will afford patient treatment that has been, until now, unattainable with the current therapeutic modalities and technologies. | $107M / Series F / May 18, 2011 | |
|
Astute Medical
|
Astute Medical is dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers that can serve as the basis for novel diagnostic tests. The Company's focus is on community and hospital-acquired acute conditions that require rapid diagnosis and risk assessment.The company's current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.Founded in 2007, the company is led by Christopher Hibberd and Paul McPherson, former members of the management at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations in 2007 for $1.7 billion. Hibberd served at Biosite for 10 years, most recently as Senior Vice President Corporate Development. Dr. McPherson was at Biosite for 14 years, most recently as Vice President Research and Development. | $13M / Series B / Mar 08, 2011 | |
NeuroVista
|
NeuroVista Corporation is a medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects roughly 3 million people in the United States. The defining characteristic of epilepsy is recurrent seizures that strike without warning. Symptoms may range from brief suspension of awareness, to lossof consciousness, to violent convulsions. Unlike other neurological conditions, such as stroke or Alzheimer's disease which tend to develop later in life, epilepsy often affects people in the prime of their lives, with the majority between 15 and 64 years of age. | $16.5M / Aug 18, 2010 | |
BARRX Medical
|
BÂRRX Medical, Inc. develops endoscopic treatment solutions for Barrett's esophagus and other chronic gastroenterological diseases. Barrett's is a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD. The company's HALOFLEX, HALO360 and HALO90 ablation systemsare designed to provide a uniform and controlled ablation effect, in order to remove diseased tissue and allow re-growth of normal cells.A multi-center randomized, sham-controlled study, published in the New England Journal of Medicine in 2009, studied HALO radiofrequency ablation applied in the highest risk Barrett's population (those having dysplasia). The ablation group had a high rate of complete eradication of dysplasia and intestinal metaplasia and a significantly decreased rate of disease progression and cancer development, as compared to the control group. In another study (AIM-II) published in Gastrointestinal Endoscopy, 98.4% of treated patients were Barrett's-free after two and a half years of follow-up.The HALO systems are cleared by the FDA for use in the United States and each have CE Mark for use in Europe. More than 58,000 procedures have been performed in over 400 hospitals around the world. Based in Sunnyvale, Calif., BÂRRX Medical, Inc. was founded in 2000 and is privately-held. | $15M / Series D / Jul 14, 2010 | |
Breathe Technologies
|
Breathe Technologies, Inc was founded in 2005 with the objective of empowering healthcare providers and patients with new, reliable and accessible respiratory therapies that optimize breathing and mobility. They are in the process of developing truly ultra-light, compact, patient-friendly ventilator systems that can transform respiratory care inthe hospital and home markets. | $23M / Series C / May 20, 2010 | |
| See all 17 investments → | |||
Co-Investors
About Delphi Ventures
Delphi Ventures is a venture capital firm that has focused on investing in biotechnology and medical devices for over two decades. With more than $1.1 billion in committed capital, Delphi Ventures has funded over 170 companies. More than 110 of our portfolio companies have either completed an initial public offering or have been acquired by aleading healthcare corporation.
Delphi Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Deepika R Pakianathan
General Partner
|
|||
Doug Roeder
General Partner
|
|||
James Bochnowski
Founder & Managing Member
|
|||
Matthew T. Potter
CFO| Partner
|
|||
|
David L. Douglass
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does David L. Douglass invest in?
David L. Douglass invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series D stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did David L. Douglass last invest?
The most recent investment recorded for David L. Douglass closed in Jan 2018. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
